Physician profile
David Irizarry
NPI 1518282839
$96,104.66
in general payments reported to CMS, 2019-2025
52 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,608 · 2020: $456 · 2021: $776 · 2022: $39K · 2023: $25K · 2024: $9,624 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Food and Beverage: $5,178 · Travel and Lodging: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,099.50 |
| Food and Beverage | $5,178.23 |
| Travel and Lodging | $1,716.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $87,657.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Intuitive Surgical, INC. | $1,388.44 | 2019 | |
| Lilly USA, LLC | $1,016.10 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $928.90 | 2019-2025 | Tepezza, Repatha, Evenity |
| Dexcom, INC. | $610.55 | 2019-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $482.78 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $392.79 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Vivus LLC | $312.50 | 2019 | |
| Insulet Corporation | $290.28 | 2019-2025 | Omnipod |
| Abbott Laboratories | $259.26 | 2022-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $219.44 | 2020-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $158.97 | 2022-2025 | |
| Beta Bionics, INC. | $156.39 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Neurocrine Biosciences, INC. | $155.38 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $144.61 | 2019-2023 | Lokelma |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $143.33 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Ibsa Pharma INC. | $125.95 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.72 | 2022-2025 | Jardiance |
| Abbvie INC. | $109.32 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $100.90 | 2022-2024 | |
| Cequr Corporation | $94.53 | 2024-2025 | Cequr Simplicity |
| Horizon Therapeutics Plc | $86.15 | 2019-2023 | Tepezza |
| Kyowa Kirin, INC. | $85.04 | 2023-2025 | Crysvita |
| Amneal Pharmaceuticals LLC | $79.21 | 2022-2025 | Unithroid |
| Corcept Therapeutics | $78.58 | 2023-2025 | Korlym |
| Esperion Therapeutics, INC. | $71.21 | 2021-2024 | Nexletol |
| Tandem Diabetes Care, INC. | $68.05 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amarin Pharma, INC. | $66.68 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $57.74 | 2025 | Yorvipath |
| Mannkind Corporation | $48.45 | 2020-2025 | |
| Ascensia Diabetes Care US INC. | $48.38 | 2023 | |
| Zealand Pharma US, INC. | $46.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.78 | 2020-2021 | |
| Amphastar Pharmaceuticals, INC. | $43.92 | 2025 | |
| Shire North American Group INC | $43.72 | 2019 | |
| Endo Pharmaceuticals INC. | $34.61 | 2019 | |
| Tolmar, INC. | $31.99 | 2024 | |
| Kvk-Tech, INC. | $29.73 | 2019 | |
| Medtronic Minimed, INC. | $29.46 | 2019 | |
| Sanofi US Services INC. | $24.74 | 2024 | |
| Sequel Med Tech, LLC | $24.54 | 2025 | Twiist |
| Globus Medical, INC. | $22.23 | 2025 | Senza |
| Chiesi USA, INC. | $20.93 | 2025 | Mycapssa |
| Antares Pharma, INC. | $19.84 | 2024 | Xyosted |
| Kowa Pharmaceuticals America, INC. | $18.69 | 2023 | Livalo |
| Aytu Biopharma, INC. | $17.49 | 2019 | |
| Intra-Sana Laboratories | $17.27 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Clarus Therapeutics INC. | $15.91 | 2021 | |
| Echosens North America, INC. | $15.79 | 2025 | Fibroscan |
| Almatica Pharma LLC | $15.09 | 2024 | Loreev Xr |
| Pfizer INC. | $12.91 | 2019 | |
| Merck Sharp & Dohme LLC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Irizarry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.